In this non-comparative trial, patients with BRAFV600-mutant resectable melanoma received either pembrolizumab alone, a sequential combination of pembrolizumab, dabrafenib and trametinib, or a concurrent combination thereof, showing encouraging clinical response rates in the concurrent therapy arm and awaiting...
2 Patients with in-transit metastasis are categorized as stage III by the American Joint Committee on Cancer (AJCC),3 and about 2% to 10% of patients initially treated for melanoma in an extremity go on to develop this pattern of disease.2 In the minority of cases, limited in-transit meta...
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care View More (COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care View More 20th Annual New York Lung Cancers...
Primary prevention measures are used with the intent to decrease or ameliorate the effects of pro-tumorgenic damage to normal tissue. Secondary prevention consists of interventions that decrease morbidity and mortality from melanoma for patients whose sk
If melanoma cells break away and spread to organs such as the lungs, liver or brain, the cancer can be cured in only a small number of patients.If treatment begins when the tumor is less than 0.75 millimeters deep, the chance of a cure is excellent. More than 95% of people with ...
In addition, we observed that the expression of innate immune response genes goes along with an increased infiltration of immune cells in melanoma patients and a better overall survival. Intriguingly, the link between NRF2 and suppression of the innate immune gene response was also observed in KEAP...
Volume 85, Issue Supplement s240, page 0, September 2007Additional Information How to Cite MISSOTTEN, G. (2007), Serum markers in screening for regional and distant metastases in conjunctival melanoma patients. Acta Ophthalmologica Scandinavica, 85: 0. doi: 10.1111/j.1600-0420.2007.01063_3527....
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010; 116: 1767-76.Ku GY, Yuan J, Page DB, Schroeder SEA, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison ...
Therapeutic resistance to immune checkpoint blockers (ICBs) in melanoma patients is a pressing issue, of which tumor loss of IFN-γ signaling genes is a major underlying mechanism. However, strategies of overcoming this resistance mechanism have been lar
Immunotherapies using bispecific T cell engagers (TCEs), which activate cytotoxic T cells to effectively eliminate cancer cells, have garnered a significant interest in treating patients with UM16. Tebentafusp, formerly known as IMCgp100, is a bispecific antibody designed to target gp100, a prot...